[6-K] Clearmind Medicine Inc. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Clearmind Medicine (CMND) filed a Form 6-K reporting it received a Nasdaq notification regarding a minimum stockholders’ equity deficiency. The filing attaches a press release titled “Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency.”

The first four paragraphs of the press release are incorporated by reference into the company’s shelf registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and its Form S-8 (File No. 333-283695).

Insights

Listing standards & disclosure analyst

Nasdaq equity deficiency notice disclosed; details not included.

Clearmind Medicine reports a Nasdaq notice tied to minimum stockholders’ equity requirements. Such notices can lead to a compliance plan or potential listing consequences if unresolved, but this excerpt provides no amounts, deadlines, or cure steps.

Because the first four press release paragraphs are incorporated into active F-3 and S-8 registrations, the company ensures these disclosures carry into current offering documents. Actual impact depends on the specifics in the incorporated press release and any subsequent compliance actions.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: November 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on November 6, 2025, titled “Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency”.

The first four paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: November 6, 2025	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3

FAQ

What did CMND disclose in this Form 6-K?

The company reported receiving a Nasdaq notification regarding a minimum stockholders’ equity deficiency and attached a related press release.

Which documents are incorporated by reference from the press release?

The first four paragraphs are incorporated into Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695).

What is the title of the attached press release for CMND?

“Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency.”

Does the filing specify corrective steps or timelines?

This excerpt does not include corrective steps or timelines; it notes receipt of the Nasdaq notification and incorporation by reference.

What is the form type and purpose of this CMND filing?

It is a Form 6-K, used by foreign private issuers to furnish current information, here about a Nasdaq equity deficiency notice.